Page 2 of pharma

India-UK FTA to Streamline Pharma & Medical Device Exports with Faster Approvals. (Image Source: Canva)

Pharma and MedTech units expect faster approvals, lower regulatory hurdles

While UK tariffs on Indian drugs are already zero, the India-UK Free Trade Agreement is set to boost pharmaceutical and…

July 24, 2025 20:26 IST

Trump plans higher global baseline tariff up to 20% as August deadline nears

Trump holds Mercedes, BMW ‘hostage,’ warns potential European car sale ban in US if drug companies don’t…

In an attempt to pull down drug prices for Americans. Donald Trump played the trade card on Tuesday, issuing a…

July 23, 2025 10:48 IST

Pharma firms flag export risks from new compliance rules

Even though the Pharmexcil doesn’t expect delay in the certification timelines, Joshi said that problem is with the transition period.

July 12, 2025 05:48 IST

AbbVie signs $700 million deal with IGI Therapeutics to co-develop new multiple myeloma drug ISB 2001

Big news: AbbVie inks $700 million pact with Glenmark arm to develop and sell new cancer drug

AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising trispecific T-cell…

July 11, 2025 11:05 IST

Lupin signs $50 million biosimilar licensing deal with Zentiva

Lupin inks $50 million licensing deal with Zentiva for global biosimilar rollout

Lupin has signed a $50 million licensing deal with Zentiva for the global commercialization of its biosimilar Certolizumab Pegol, targeting…

July 9, 2025 11:00 IST

Sun Pharma, pharma industry, Dilip Shanghvi, USFDA, manufacturing, compliance issues, US FDA inspection, R&D spend, revenue, specialty revenue

Sun Pharma steps up USFDA compliance drive: What’s changing at Halol, Mohali and Dadra?

Sun Pharma is stepping up regulatory compliance efforts at three USFDA-flagged facilities, including Halol, Mohali, and Dadra.

July 8, 2025 11:07 IST

Apollo Hospitals, pharmacy business, pharma sector, healthcare sector, demerger, listing, digital business, subsidiaries, NewCo, Apollo HealthCo Ltd, turnover

Demerger announcement: Apollo Hospitals to list digital & pharmacy biz in 18-21 months

Apollo Hospitals plans to spin off and list its digital and pharmacy businesses within 18–21 months, aiming to unlock value…

Updated: July 1, 2025 11:37 IST

Lupin, pharma sector, pharma, ANDA, drug, US FDA, Chronic Idiopathic Constipation, Prucalopride Tablets

Lupin gets US FDA nod for constipation drug Prucalopride tablets

Lupin has received USFDA approval for its ANDA for Prucalopride Tablets, used to treat Chronic Idiopathic Constipation in adults.

Updated: June 25, 2025 15:13 IST

What is Cipla’s prescription for FY26 after 22 patent grants? 5 key takeaways from FY25 annual report

Cipla aims for FY26 growth via inorganic expansion and new product launches, especially 2-3 peptide assets. Its FY25 report highlights…

June 25, 2025 14:53 IST

Lupin expands China business: Signs pact with Sino Universal Pharm for lung medicines

While the Sino Universal Pharmaceuticals will get the necessary regulatory approval from the Chinese authorities, Lupin will be responsible for…

June 16, 2025 17:19 IST

Sun Pharma, pharma industry, Halol facility, inspection, US FDA, Good Manufacturing Practices, import, leadership change, managing director, appointment

Compliance review: US FDA issues 8 observations for Sun Pharma’s Halol plant following GMP inspection

Sun Pharma said the US FDA issued a Form-483 with eight observations after inspecting its Halol facility from June 2–13.

Updated: June 16, 2025 10:13 IST

5 pharma CDMO stocks to watch out for in 2025

Here is a list of some of the 5 best CDMO stocks in India.

Updated: June 11, 2025 13:23 IST

Dr Reddy’s Laboratories, cancer drug, Keytruda, partnership, Alvotech, biosimilar, license agreement, manufacturing

Dr Reddy’s, Alvotech partner to develop and commercialize biosimilar of cancer drug Keytruda

Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda…

Updated: June 5, 2025 10:29 IST

Is Zydus Lifesciences heading for a 10% decline in 12 months? Nuvama reveals 3 key reasons

Nuvama downgrades Zydus Lifesciences: Nuvama predicts a 10% drop in Zydus Lifesciences’ stock; explore the reasons now!

June 5, 2025 09:31 IST

Zydus Lifesciences, Pharmaceutical, healthcare, pharma, health

With plans to acquire US-based genus Inc, Zydus Lifesciences set to enter the global biologics CDMO business

Zydus Lifesciences plans to acquire US-based Agenus Inc, entering the global biologics CDMO market with two California facilities. The deal…

June 4, 2025 05:09 IST

'Feels like a curse': Indian worker sparks debate about 90 day notice period, Redditors say they never tell HR about...

Nuvama-Cushman fund buys office space in Delhi for Rs 763 crore from Kotak arm

Nuvama-Cushman Prime Offices Fund acquires premium Grade A office space in Delhi’s Saket for Rs 763 crore from Kotak consortium.…

May 27, 2025 23:34 IST

pharma sector, Jan Aushadhi, branded pharmaceutical market, volume growth, trade generics, pharmacy chains, acquisitions

Can branded pharma keep pace as Jan Aushadhi scales up? Kotak flags long-term growth risks

India’s branded pharma market is under pressure as Jan Aushadhi and other generic channels gain momentum, impacting volume growth.

Updated: May 22, 2025 10:21 IST

Related News

GST cut backfired? your health insurance premium may go up by up to 5 pc, says report

Govt extended ITR AY 2025-26 deadline, but only 4.56 crore returns filed so far

iPhone 17, iPhone 17 Pro, iPhone 17 Air, iPhone 17 Pro Max colours revealed: Orange, dark blue, purple and more

credit cards, forex, foreign exchange, zero-forex, GST, travel card

The costliest chai in India: How credit cards sell you the lounge dream

Indian railways, technology, railways. PM Modi, travel,

AI on Track: How technology is transforming Indian Railways

‘People decide the narrative…’: Musk fact-checks Navarro on India’s Russian oil imports

World News34 min ago

Elon Musk and Peter Navarro’s feud intensifies as fact-checkers flag Navarro’s post on India’s oil imports on Musk’s social media platform. Musk defends the platform’s approach, emphasizing the power of people to shape the narrative and subject even influential figures like Navarro to fact-checking.

View all shorts